Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
about
Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease InhibitorsWide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency.Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance.Human Immunodeficiency Virus Resistance Testing Technologies and Their Applicability in Resource-Limited Settings of Africa.Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya.Role of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing
P2860
Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Contribution of Gag and Protea ...... tease Inhibitor-Based Therapy.
@ast
Contribution of Gag and Protea ...... tease Inhibitor-Based Therapy.
@en
type
label
Contribution of Gag and Protea ...... tease Inhibitor-Based Therapy.
@ast
Contribution of Gag and Protea ...... tease Inhibitor-Based Therapy.
@en
prefLabel
Contribution of Gag and Protea ...... tease Inhibitor-Based Therapy.
@ast
Contribution of Gag and Protea ...... tease Inhibitor-Based Therapy.
@en
P2093
P2860
P50
P356
P1476
Contribution of Gag and Protea ...... otease Inhibitor-Based Therapy
@en
P2093
Chris M Parry
Gillian Hunt
Katherine Sutherland
Lynn Morris
Patricia A Cane
P2860
P304
P356
10.1128/AAC.02682-15
P407
P577
2016-03-25T00:00:00Z